- Home
- SFL vs NVCR Comparison
SFL vs NVCR Comparison
Compare SFL & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- NVCR
- Stock Information
- Founded
- SFL 2003
- NVCR 2000
- Country
- SFL Bermuda
- NVCR Switzerland
- Employees
- SFL N/A
- NVCR N/A
- Industry
- SFL Marine Transportation
- NVCR Medical/Dental Instruments
- Sector
- SFL Consumer Discretionary
- NVCR Health Care
- Exchange
- SFL Nasdaq
- NVCR Nasdaq
- Market Cap
- SFL 1.1B
- NVCR 1.9B
- IPO Year
- SFL N/A
- NVCR 2015
- Fundamental
- Price
- SFL $9.23
- NVCR $17.60
- Analyst Decision
- SFL Strong Buy
- NVCR Buy
- Analyst Count
- SFL 1
- NVCR 7
- Target Price
- SFL $13.00
- NVCR $32.43
- AVG Volume (30 Days)
- SFL 1.2M
- NVCR 1.4M
- Earning Date
- SFL 08-13-2025
- NVCR 07-24-2025
- Dividend Yield
- SFL 11.93%
- NVCR N/A
- EPS Growth
- SFL N/A
- NVCR N/A
- EPS
- SFL 0.41
- NVCR N/A
- Revenue
- SFL $852,590,000.00
- NVCR $621,711,000.00
- Revenue This Year
- SFL N/A
- NVCR $5.56
- Revenue Next Year
- SFL $3.20
- NVCR $9.19
- P/E Ratio
- SFL $22.30
- NVCR N/A
- Revenue Growth
- SFL 6.58
- NVCR 18.27
- 52 Week Low
- SFL $6.78
- NVCR $14.17
- 52 Week High
- SFL $14.05
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- SFL 65.76
- NVCR 49.74
- Support Level
- SFL $8.79
- NVCR $16.81
- Resistance Level
- SFL $9.07
- NVCR $18.59
- Average True Range (ATR)
- SFL 0.21
- NVCR 0.74
- MACD
- SFL 0.05
- NVCR 0.08
- Stochastic Oscillator
- SFL 98.48
- NVCR 56.18
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.